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Introduction 
Polybrominated diphenylethers (PBDEs) are widely used as flame retardants in polymer 
materials, textiles, electronic boards and various other materials. Technical PBDE 
preparations are produced as mixtures of mainly penta-, octa- or decabrombiphenyl 
ethers1,2. PBDEs are structurally similar to other environmental pollutants like dioxins 
and PCBs, they are lipophilic and persistent compounds and are widespread in the 
environment.  
 
To date, no information is available on the levels of PBDEs in human serum in 
Australia.  In 2003, more than 9000 blood samples were collected in Australia as part of 
the National Dioxins Program.  The aim of this study was to evaluate PBDE 
concentrations in these samples, focusing on one age group. 
Methods and Materials 
 
Sampling and samples 
Serum samples were collected by a Brisbane based private pathology company, 
Sullivan and Nicolaides Pathology, from stored sera that had been collected as part of 
their routine testing procedures.  It should be noted that throughout this paper serum 
specimens are referred to as samples.  The samples were obtained from males and 
females aged 31-45 years according to the geographic stratification criteria presented in 
Figure 1 and outlined below: 
• Four urban regions: 
– Northeast (including Brisbane, Tweed and Gold Coast and major population 
centres in Queensland) 
– Southeast (Sydney, Canberra, Wollongong, Newcastle and other major 
population centres from New South Wales) 
– South (Melbourne, Adelaide, Hobart and other major population centres from 
Victoria) 
– West (Perth and other major population centres in Western Australia) 
• One rural region: 
– Including rural areas from all States and the Northern Territory.  Rural areas 
were defined as those postcodes outside metropolitan or major regional centres. 
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Figure 1. The stratification approach indicating the sampling regions of four major 
population areas of Australia.   
 
For all regions except the Northeast females (n=99) and the South males (n=98), there 
were 100 samples in each pool constructed by taking about 1 mL of each individual 
serum sample.  
 
Ethics 
The project was submitted to The University of Queensland Medical Research Ethics 
Committee Approval and approval was obtained on the 20th September 2002.  The 
project was allocated Clearance Number 2002000656.   
 
Sample storage 
Prior to shipping, samples were stored at -30 degrees Celsius at the National Research 
Centre for Environmental Toxicology.  Samples were air freighted, frozen on dry ice, 
and shipped to Health Canada for analysis. 
 
Analytical Methodology 
All analyses were performed as described previously.3 In summary the method involved 
the addition of isotopically labelled PBDEs followed by denaturing of the sera with 
aqueous ammonium sulfate and extraction with ethanol-hexane. The lipid was measured 
gravimetrically and then removed with strong acid. Further purification was 
accomplished on columns of acid silica and activated Florisil. The PBDEs were 
identified and determined by gas chromatography with high resolution (8-10K) mass 
spectrometry in the electron impact mode. Sample batches included a laboratory reagent 
blank which is significant for PBDEs (the total in the blank is subtracted from the total 
in the sample) and a reference or repeat control sample for accuracy and precision. The 
laboratory has participated successfully in both international interlaboratory studies for 
PBDEs sponsored by the flame retardant industry (BSEF).  
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 Results and Discussion 
The concentrations of PBDE congeners in blood sera collected from Australians aged 
31-45 years are presented in Table 1 and Figure 2. PBDEs were detected in samples 
from all regions. The average total concentration (sum of 13 PBDEs) across all samples 
was 11.0 ± 3.0 ng g-1.  Overall concentration ranged from 6.7 ng g-1 lipid in a pooled 
sample collected from females from the South region to a maximum of 18 ng g-1 lipid in 
a pooled sample collected from males in the West region.  BDE 47 contributed the most 
to the total PBDE concentration averaging 41% (39-45%) of the total congener 
concentration. PBDEs 99 and 153 contributed an average of 20% (16-26%) and 18% 
(12-20%), respectively, to the total concentration of the 13 PBDEs.  Similar congener 
profiles have been reported in other studies conducted in Canada, North America, Japan 
and Europe 3- 6.  
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Figure 2.  Concentrations of BDE congeners detected in blood sera from Australians 
aged 31-45 years.  Values are expressed in ng g-1 lipid based. 
 
To our knowledge, PBDEs are not produced in Australia and hence it is surprising that 
the concentrations of PBDEs in Australian sera are high, for example, when compared 
to concentrations reported in European milk or blood.  Notably, analysis of PBDEs in 
selected samples of Australian pig fat, which showed previously unknown components, 
also found high concentrations of PBDEs 7. Levels of PBDEs in Sweden have decreased 
slightly since a peak in 1997.  This may be due to a “voluntary” ban on penta-BDE 
products in Sweden and some other European countries since the 1990’s 8.  The levels 
reported here for Australian serum, are lower than those reported for North America and 
Canada 3,4.  Table 1 compares concentrations of PBDEs detected in breast milk and 
blood from various countries.  It is worth noting that in contrast to the commercial 
mixture where they are present in equal amounts, the concentration of BDE 47 is higher 
than that of BDE 99, indicative of bioincorporation of the PBDEs rather than a sampling 
or analysis issue.   The results of this study indicate that more detailed investigation of 
the levels of PBDEs in the Australian population is warranted. 
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 Table 1. Mean concentrations of PBDEs (ng g-1 lipid) in blood (B) and breast milk (M) 
detected in other studies.   
Area Collection year  n 
Sum 
PBDE BDE 47 BDE 99 BDE 153 BDE 154 
Australiaa 2003 B 10b 11.0 4.7 2.3 2.0 0.2 
Japan5 Unknown M 12 1.3 - - - - 
Sweden9 1997 B 20 5.4 1.6 - 0.6 0.4 
Sweden6 2000 M 40 2.8 1.7 0.2 0.5 0.02 
Norway10 1999 B 1b 3.3 1.5 0.31 0.6 0.4 
Germany12 2000 M 7 1.8 0.7 0.2 0.5 - 
UK13 2001/03 M 52 6.6c 3.0c 0.9c 1.4c 0.5c 
Canada3,4 1992 M 72 3.0c 1.4c 0.5c 0.3c - 
Canada3,4 2001-02 M 98 22c 12.9c 3.3c 1.3c 0.2c 
USA11 2001 B 12 37c 28c 5.7c 2.9c 0.3c 
USA4 2002 M 47 34c 18c 5.7c 2.0c 0.2c 
a – current study, b- number of pools, c - median 
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